Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effects (good or bad) of Campath-1H
antibody in the treatment of lymphoplasmacytic lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Arizona Oncology Associates Bayer Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital Northwestern University University of California, Los Angeles